A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
- Conditions
- Obesity
- Interventions
- Registration Number
- NCT05567796
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms.
Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 3400
- Male or female
- Age above or equal to 18 years at the time of signing informed consent
- Body mass index (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m^2) or b) BMI greater than or equal to 27.0 kg/m^2 with the presence of at least one weight-related comorbidity including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
- Glycaemia related: a) Glycated Haemoglobin (HbA1c) greater than or equal to 6.5 percent (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening b) History of type 1 or type 2 diabetes mellitus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cagrisema Cagrilintide Participants will receive cagrilintide and semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks. Cagrisema Semaglutide Participants will receive cagrilintide and semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks. Cagrilintide Cagrilintide Participants will receive cagrilintide s.c. and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks. Cagrilintide Placebo semaglutide Participants will receive cagrilintide s.c. and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks. Semaglutide Semaglutide Participants will receive semaglutide s.c.and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks. Semaglutide Placebo cagrilintide Participants will receive semaglutide s.c.and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks. Placebo s.c. Placebo cagrilintide Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks. Placebo s.c. Placebo semaglutide Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks.
- Primary Outcome Measures
Name Time Method CagriSema versus placebo: Relative change in body weight From baseline (week 0) to end of treatment (week 68) Measured in percentage (%)
CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction From baseline (week 0) to end of treatment (week 68) Measured as count of participants
- Secondary Outcome Measures
Name Time Method CagriSema versus placebo: Change in IWQOL-Lite-CT - Physical Function Score From baseline (week 0) to end of treatment (week 68) Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
CagriSema versus placebo: Change in IWQOL-Lite-CT - Psychosocial Score From baseline (week 0) to end of treatment (week 68) Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
CagriSema versus placebo: Achievement of at least 14.6- point increase (yes/no) in IWQOL-Lite-CT Physical Function score From baseline (week 0) to end of treatment (week 68) Measured as count of participants. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
CagriSema versus placebo: Change in IWQOL-Lite-CT - Total Score From baseline (week 0) to end of treatment (week 68) Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
CagriSema versus placebo: Change in SF-v2 Health Survey Acute (SF-36 v2 Acute) Physical Functioning Score From baseline (week 0) to end of treatment (week 68) Measured as score points. The SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being.
CagriSema versus placebo, semaglutide and cagrilintide: Change in body weight From baseline (week 0) to end of treatment (week 68) Measured in kilograms (kg)
CagriSema versus placebo, semalutide and cagrilintide: Change in body mass index (BMI) From baseline (week 0) to end of treatment (week 68) Measured in kilogram per square meter (kg/m\^2)
CagriSema versus placebo, semaglutide and cagrilintide: Improvement in weight category From baseline (week 0) to end of treatment (week 68) Measured as count of participants. The categories are: BMI, underweight less than (\<) 18.5, normal weight 18.5 to \<25, overweight 25.0 to \<30, obesity class I 30 to \< 35, obesity class II 35 to \< 40, obesity class III \>40.
CagriSema versus placebo: Change in Glycated Haemoglobin (HbA1c) From baseline (week 0) to end of treatment (week 68) Measured as percentage (%)
CagriSema versus placebo: Change in HbA1c From baseline (week 0) to end of treatment (week 68) Measured as millimoles per mole (mmol/mol).
CagriSema versus placebo: Change in Fasting Plasma Glucose (FPG) (mmol/L). From baseline (week 0) to end of treatment (week 68) Measured as millimoles per liter (mmol/L).
CagriSema versus placebo: Change in FPG (mg/dL) From baseline (week 0) to end of treatment (week 68) Measured as milligrams per deciliter (mg/dL).
CagriSema versus placebo: Achievement of at least 3.7-point increase (yes/no) in SF-36v2 Physical Functioning score From baseline (week 0) to end of treatment (week 68) Measured as count of participants. The SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being.
CagriSema versus placebo: Achievement of >= 20% weight reduction From baseline (week 0) to end of treatment (week 68) Measured as count of participant
CagriSema versus placebo: Achievement of >= 25% weight reduction From baseline (week 0) to end of treatment (week 68) Measured as count of participant
CagriSema versus placebo: Achievement of >= 30% weight reduction From baseline (week 0) to end of treatment (week 68) Measured as count of participant
CagriSema versus placebo: Ratio to baseline in fasting serum insulin From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus cagrilintide and CagriSema versus semaglutide: Relative change in body weight From baseline (week 0) to end of treatment (week 68) Measured as percentage (%)
CagriSema versus placebo: Relative change in body weight From baseline (week 0) to week 20 Measured as percentage (%)
CagriSema versus placebo: Change in waist circumference From baseline (week 0) to end of treatment (week 68) Measured in centimeters (cm)
CagriSema versus placebo: Change in Diastolic Blood Pressure (DBP) From baseline (week 0) to end of treatment (week 68) Measured in mmHg
CagriSema versus placebo: Change in systolic blood pressure (SBP) From baseline (week 0) to end of treatment (week 68) Measured in millimeters of mercury (mmHg)
CagriSema versus placebo: Ratio to baseline in total cholesterol From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus placebo: Ratio to baseline in High-density lipoprotein (HDL) cholesterol From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus placebo: Ratio to baseline in Low-density lipoprotein (LDL) cholesterol From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus placebo: Ratio to baseline in Very low-density lipoprotein (VLDL) cholesterol From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus placebo: Ratio to baseline in Triglycerides From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus placebo: Ratio to baseline in Free fatty acids From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus semaglutide and cagrilintide: Change in waist circumference From baseline (week 0) to end of treatment (week 68) Measured in centimeters (cm)
CagriSema versus semaglutide and cagrilintide: Change in SBP From baseline (week 0) to end of treatment (week 68) Measured in mmHg
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in total cholesterol From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in HDL From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in LDL From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in VLDL From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Triglycerides From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Free fatty acids From baseline (week 0) to end of treatment (week 68) Measured as ratio
CagriSema versus placebo: Relative change in body weight (Measured in kilograms (kg)) From baseline (week 0) to end of treatment (week 68) Measured in kilograms (kg).
CagriSema versus placebo: Relative change in body weight (Measured in percentage (%)) From baseline (week 0) to end of treatment (week 68) Measured in percentage (%).
CagriSema versus placebo: Absolute change in body weight (Measured in kilograms (kg)) From baseline (week 0) to end of treatment (week 68) Measured in kilograms (kg).
CagriSema versus placebo: Absolute change in body weight (Measured in percentage (%)) From baseline (week 0) to end of treatment (week 68) Measured in percentage (%).
CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as kilograms (kg)) From baseline (week 0) to end of treatment (week 68) Measured as kilograms (kg)
CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as percentage (%)) From baseline (week 0) to end of treatment (week 68) Measured as percentage (%)
CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as kilograms (kg)) From baseline (week 0) to end of treatment (week 68) Measured as kilograms (kg)
CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as percentage (%)) From baseline (week 0) to end of treatment (week 68) Measured as percentage (%)
CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as percentage (%)) From baseline (week 0) to end of treatment (week 68) Measured as percentage (%)
CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as %-points) From baseline (week 0) to end of treatment (week 68) Measured as %-points
CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as percentage (%)) From baseline (week 0) to end of treatment (week 68) Measured as percentage (%).
CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as %-points) From baseline (week 0) to end of treatment (week 68) Measured as %-points
CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in kilograms (kg)) From baseline (week 0) to end of treatment (week 68) Measured in kilograms (kg)
CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in percentage (%)) From baseline (week 0) to end of treatment (week 68) Measured in percentage (%)
CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in kilograms (kg)) From baseline (week 0) to end of treatment (week 68) Measured in kilograms (kg)
CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in percentage (%)) From baseline (week 0) to end of treatment (week 68) Measured in percentage (%)
CagriSema versus placebo: Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score From baseline (week 0) to end of treatment (week 68) Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
Change in Control of Eating (COEQ): Craving Control Score From baseline (week 0) to end of treatment (week 68) Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Change in COEQ: Craving for Savoury food score From baseline (week 0) to end of treatment (week 68) Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Change in COEQ: Hunger score From baseline (week 0) to end of treatment (week 68) Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Change in COEQ: Craving for Sweets Score From baseline (week 0) to end of treatment (week 68) Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Change in COEQ: Positive Mood score From baseline (week 0) to end of treatment (week 68) Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Change in COEQ: Satiety score From baseline (week 0) to end of treatment (week 68) Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Change in IWQOL-Lite-CT Physical Function score From baseline (week 0) to end of treatment (week 68) Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite-CT Physical Function score From baseline (week 0) to end of treatment (week 68) Measured as count of participants.
CagriSema versus placebo, semalutide and cagrilintide: Ratio to baseline C-reactive protein (CRP) From baseline (week 0) to end of treatment (week 68) Measured as ratio
Number of Treatment Emergent Adverse Events (TEAEs) From baseline (week 0) to end of study-main part (week 75) Measured as count of events
Number of Treatment Emergent Serious adverse events (TESAEs) From baseline (week 0) to end of study-main part (week 75) Measured as count of events.
Trial Locations
- Locations (218)
Momentum Clinical Research
🇦🇺Taringa, Queensland, Australia
Imeldaziekenhuis - Bonheiden - Department of Endocrinology
🇧🇪Bonheiden, Belgium
CHR Mons-Hainaut - Site Warquignies
🇧🇪Boussu, Belgium
CHU Helora - Site Warquignies
🇧🇪Boussu, Belgium
Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie
🇧🇪Bruxelles, Belgium
UZ Antwerpen - UZA - Department of Endocrinology
🇧🇪Edegem, Belgium
UZA - UZ Antwerpen - Department of Endocrinology
🇧🇪Edegem, Belgium
UZ Gent - Endocrinologie
🇧🇪Gent, Belgium
UZ Leuven - Endocrinology
🇧🇪Leuven, Belgium
Medical centre Asclepius
🇧🇬Dupnitsa, Kyustendil, Bulgaria
"Multiprofile hospital for active treatment Puls" AD
🇧🇬Blagoevgrad, Bulgaria
"Outpatient clinic for Individual Practice for Specialized Outpatient Medical Care - Endocrinology NT" EOOD
🇧🇬Montana, Bulgaria
OCSOMCE - Dr. Albena Dinkova EOOD
🇧🇬Pleven, Bulgaria
"Diagnostic - consulting center iztok" EOOD
🇧🇬Plovdiv, Bulgaria
ASOMCEM - IP - Dr. Antoanela Slavcheva
🇧🇬Ruse, Bulgaria
"Nader Yabrudi - ASMPVBE Individual practice"
🇧🇬Smolyan, Bulgaria
UMHAT "Aleksandrovska"
🇧🇬Sofia, Bulgaria
USHATE "Acad. Ivan Penchev" First Clinic of Endocrinology
🇧🇬Sofia, Bulgaria
USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
🇧🇬Sofia, Bulgaria
"Diagnostic - consulting center 18 - Sofia" EOOD
🇧🇬Sofia, Bulgaria
"UMHAT "Tsaritsa Yoanna-ISUL"" EAD, Clinic of endocrinology and metabolic disease for metabolic disorders treatment
🇧🇬Sofia, Bulgaria
"DCC XX - Sofia" EOOD, Endocrinology Consulting Room
🇧🇬Sofia, Bulgaria
AIPSMC Dr. Artin Magardichyan EOOD
🇧🇬Varna, Bulgaria
Medical center Berbatov
🇧🇬Yambol, Bulgaria
C-endo Diab & Endo Clinic
🇨🇦Edmonton, Alberta, Canada
Synergy Wellness Clinic
🇨🇦Sherwood Park, Alberta, Canada
Ocean West Research Clinic
🇨🇦Surrey, British Columbia, Canada
Dr. M.B. Jones Inc
🇨🇦Victoria, British Columbia, Canada
G.A. Research Associates Ltd.
🇨🇦Moncton, New Brunswick, Canada
Nova Scotia Hlth Halifax
🇨🇦Halifax, Nova Scotia, Canada
Wockhardt Hospital, Mumbai Central
🇮🇳Mumbai, Maharashtra, India
Grant Medical Foundation Ruby Hall Clinic
🇮🇳Pune, Maharashtra, India
Deenanath Mangeshkar Hospital & Research Centre
🇮🇳Pune, Maharashtra, India
Sahyadri Super Speciality Hospital
🇮🇳Pune, Maharashtra, India
chelleram Diabetes Institute
🇮🇳Pune, Maharashtra, India
Clinica Universitaria de Navarra
🇪🇸Pamplona, Navarra, Spain
Hospital Clinic i Provincial
🇪🇸Barcelona, Spain
Hospital Vithas Sevilla
🇪🇸Castilleja Dela Cuesta Sevilla, Spain
Hospital de León
🇪🇸León, Spain
Hospital Gregorio Marañón
🇪🇸Madrid, Spain
Clínica Nuevas Tecnologías en Diabetes y Endocrinología
🇪🇸Sevilla, Spain
Hospital Infanta Luisa
🇪🇸Sevilla, Spain
China Medical University Hospital
🇨🇳Taichung, Taiwan
National Taiwan University Hospital
🇨🇳Taipei City, Taiwan
Baskent University Ankara Hospital
🇹🇷Ankara, Cankaya, Turkey
T.C. Saglık Bakanlıgı Adana Sehir Egitim ve Arastirma Hastan
🇹🇷Adana, Turkey
Baskent Universitesi Adana
🇹🇷Adana, Turkey
Ankara Sehir Hastanesi Dahiliye Klinigi
🇹🇷Ankara, Turkey
Akdeniz University Tip Fakultesi Hastanesi
🇹🇷Antalya, Turkey
Hatay Mustafa Kemal Universitesi Saglik Uygulama ve Arastirm
🇹🇷Hatay, Turkey
Istanbul Universitesi Istanbul Tip Fakultesi - Endokrinoloji
🇹🇷Istanbul, Turkey
TC SB Ist.İl Sag.Müd.Prof.Dr.Cemil Tascioglu Sehir Hastanesi
🇹🇷Istanbul, Turkey
Haydarpasa Numune Egitim Arastirma Hastanesi Endokrinoloji
🇹🇷Istanbul, Turkey
T.C SB Goztepe Prof. Dr. Suleyman Yalcin City Hospital
🇹🇷Istanbul, Turkey
Sivas Cumhuriyet Univesity Endocrinology Department
🇹🇷Sivas, Turkey
Layton Medical Centre
🇬🇧Blackpool, United Kingdom
Univ of Alabama Birmingham
🇺🇸Birmingham, Alabama, United States
Velocity Clin Res Los Angeles
🇺🇸Los Angeles, California, United States
Velocity Clin Res Wstlke
🇺🇸Los Angeles, California, United States
Univ of Colorado at Denver
🇺🇸Aurora, Colorado, United States
New West Physicians,Inc.
🇺🇸Golden, Colorado, United States
Northeast Research Institute
🇺🇸Fleming Island, Florida, United States
South Broward Research LLC
🇺🇸Miramar, Florida, United States
Clinical Neuroscience Solution
🇺🇸Orlando, Florida, United States
Florida Inst For Clin Res
🇺🇸Orlando, Florida, United States
Clinical Trial Res Assoc,Inc
🇺🇸Plantation, Florida, United States
Hope Clin Res & Wellness
🇺🇸Conyers, Georgia, United States
East West Med Res Inst
🇺🇸Honolulu, Hawaii, United States
Great Lakes Clinical Trials
🇺🇸Chicago, Illinois, United States
Endeavor Health
🇺🇸Skokie, Illinois, United States
Evanston Premier Hlthcr Res
🇺🇸Skokie, Illinois, United States
Midwest Inst For Clin Res
🇺🇸Indianapolis, Indiana, United States
Northern Pines Hlth Ctr, PC
🇺🇸Buckley, Michigan, United States
StudyMetrix Research LLC
🇺🇸Saint Peters, Missouri, United States
Comprehensive Weight Ctrl Prog
🇺🇸New York, New York, United States
Velocity Clinical Res. Inc Vestal
🇺🇸Vestal, New York, United States
University of North Carolina
🇺🇸Chapel Hill, North Carolina, United States
Medication Mgmnt, LLC_Grnsboro
🇺🇸Greensboro, North Carolina, United States
PharmQuest Life Sciences LLC
🇺🇸Greensboro, North Carolina, United States
Accellacare_NC
🇺🇸Raleigh, North Carolina, United States
Accellacare
🇺🇸Wilmington, North Carolina, United States
New Venture Medical Research
🇺🇸Wadsworth, Ohio, United States
Lynn Institute of Norman
🇺🇸Norman, Oklahoma, United States
The University of Penn Center
🇺🇸Philadelphia, Pennsylvania, United States
Clinical Res Collaborative
🇺🇸Cumberland, Rhode Island, United States
Medical Uni of SC Charleston
🇺🇸Charleston, South Carolina, United States
Coastal Carolina Res Ctr
🇺🇸North Charleston, South Carolina, United States
Hillcrest Clinical Research
🇺🇸Simpsonville, South Carolina, United States
Spartanburg Medical Research
🇺🇸Spartanburg, South Carolina, United States
Holston Medical Group_Bristol
🇺🇸Bristol, Tennessee, United States
Holston Medical Group
🇺🇸Kingsport, Tennessee, United States
Baylr Sctt White Rs Inst, Endo
🇺🇸Dallas, Texas, United States
Velocity Clinical Res-Dallas
🇺🇸Dallas, Texas, United States
UT Southwestern Med Cntr
🇺🇸Dallas, Texas, United States
DCOL Ctr for Clin Res
🇺🇸Longview, Texas, United States
Washington Cntr Weight Mgmt
🇺🇸Arlington, Virginia, United States
Health Res of Hampton Roads
🇺🇸Newport News, Virginia, United States
Selma Medical Associates
🇺🇸Winchester, Virginia, United States
Capital Clin Res Ctr,LLC
🇺🇸Olympia, Washington, United States
Rainier Clin Res Ctr Inc
🇺🇸Renton, Washington, United States
Fundación CESIM
🇦🇷Santa Rosa, La Pampa, Argentina
Centro de Investigación Clínica
🇦🇷Caba, Argentina
Centro Médico Viamonte SRL
🇦🇷Caba, Argentina
Instituto Centenario
🇦🇷Ciudad de Buenos Aires, Argentina
Sanatorio Norte
🇦🇷Santiago del Estero, Argentina
Northern Beaches Clinical Research
🇦🇺Brookvale, New South Wales, Australia
Momentum Clinical Research Darlinghurst
🇦🇺Darlinghurst, New South Wales, Australia
Novatrials
🇦🇺Kotara, New South Wales, Australia
Premier Clinical Trial Research Network (PCTRN)
🇨🇦Hamilton, Ontario, Canada
Aarhus Universitetshospital Diabetes og Hormonsygdomme
🇩🇰Aarhus N, Denmark
Sydvestjysk Sygehus Esbjerg
🇩🇰Esbjerg, Denmark
Center for Klinisk Metabolisk Forskning
🇩🇰Hellerup, Denmark
Hvidovre Hospital Endokrinologisk forsknings afsnit 159
🇩🇰Hvidovre, Denmark
Sjællands Universitetshospital
🇩🇰Køge, Denmark
HUS Clinical Research Biomedicum 2U
🇫🇮Helsinki, Finland
Health Step Finland Oy
🇫🇮Kuopio, Finland
OYS Sisätautien tutkimusyksikkö
🇫🇮Oulu, Finland
Turku University Hospital
🇫🇮Turku, Finland
Aphp-Hopital La Pitie Salpetriere-3
🇫🇷Paris, France
Hospices Civils de Lyon-Hopital Lyon Sud-1
🇫🇷Pierre-Benite, France
Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-1
🇫🇷Saint Herblain, France
Les Hopitaux Universitaires de Strasbourg-Hopital de Hautepierre-1
🇫🇷Strasbourg cedex 2, France
Centre de Recherche Clinique Portes Du Sud
🇫🇷Venissieux, France
Diabetespraxis Mergentheim
🇩🇪Bad Mergentheim, Germany
Zentrum fuer klinische Studien Suedbrandenburg GmbH
🇩🇪Elsterwerda, Germany
InnoDiab Forschung GmbH
🇩🇪Essen, Germany
Wendisch/Dahl Hamburg
🇩🇪Hamburg, Germany
Universitätsklinikum Leipzig - Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie
🇩🇪Leipzig, Germany
AmBeNet GmbH
🇩🇪Leipzig, Germany
Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
🇩🇪Münster, Germany
Erlinger
🇩🇪Stuttgart, Germany
Zentrum für klinische Studien Allgäu Oberschwaben
🇩🇪Wangen, Germany
Nirmal Hospital Pvt. Ltd.
🇮🇳Surat, Gujarat, India
Government Medical College, Kozhikode
🇮🇳Kozhikode, Kerala, India
Sir H. N. Reliance Foundation Hospital and Research Centre
🇮🇳Mumbai, Maharashtra, India
Maulana Azad Medical College
🇮🇳Delhi, New Delhi, India
SMS Medical College & Hospital
🇮🇳Jaipur, Rajasthan, India
Eternal Heart Care Centre
🇮🇳Jaipur, Rajasthan, India
Christian Medical College Hospital, Vellore
🇮🇳Vellore, Tamil Nadu, India
All India Institute of Medical Sciences_New Dehli
🇮🇳Delhi, India
Osmania General Hospital
🇮🇳Hyderabad, India
Azienda Ospedaliero-Universitaria Renato Dulbecco
🇮🇹Catanzaro, Cz, Italy
Policlinico San Donato
🇮🇹San Donato Milanese (MI), Lombardia, Italy
Pol. Uni. Campus Biomedico
🇮🇹Roma, RM, Italy
Azienda Ospedaliera Universitaria Senese
🇮🇹Siena, SI, Italy
A.O.Universitaria S.ORSOLA-MALPIGHI - U.O.Endocrinologia e Cura
🇮🇹Bologna, Italy
ARNAS (Azienda Ospedaliera di Rilievo Nazionale di Alta Specializzazione) Ospedale Garibaldi
🇮🇹Catania, Italy
Azienda Ospedaliera di Padova Clin.Med.3
🇮🇹Padova, Italy
Policlinico Universitario Tor Vergata
🇮🇹Roma, Italy
Azienda Ospedaliera Universitaria Policlinico Umberto I
🇮🇹Roma, Italy
Iryouhoujinsyadan Shoureikan Shinsapporo Seiryou Hospital
🇯🇵Sapporo city, Hokkaido, Japan
OCROM Clinic
🇯🇵Suita-shi, Osaka, Japan
TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
🇯🇵Aichi, Japan
Chiba University Hospital_Diabetes, Metabolism and Endocrinology
🇯🇵Chiba-shi, Chiba, Japan
Kawada Clinic
🇯🇵Gunma, Japan
Motomachi Takatsuka Naika Clinic_Internal Medicine
🇯🇵Kanagawa, Japan
Osaka NISHI-UMEDA Clinic
🇯🇵Osaka, Japan
Asano Clinic
🇯🇵Saitama, Japan
Shinden Higashi Clinic
🇯🇵Sendai-shi, Miyagi, Japan
Tokyo-Eki Center-building Clinic
🇯🇵Tokyo, Japan
Fukuwa Clinic
🇯🇵Tokyo, Japan
Miho Clinic
🇯🇵Tokyo, Japan
ToCROM Clinic
🇯🇵Tokyo, Japan
Higashi-shinjuku clinic
🇯🇵Tokyo, Japan
The catholic university of Korea, Bucheon St.Mary's Hospital
🇰🇷Bucheon-si, Gyeonggi-do, Korea, Republic of
Kyungpook National University Hospital
🇰🇷Daegu, Korea, Republic of
Daejeon Eulji Medical Center, Eulji University
🇰🇷Daejeon, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Pusan National University Yangsan Hospital
🇰🇷Yangsan, Korea, Republic of
Arechavaleta Granell María del Rosario
🇲🇽Guadalajara, Jalisco, Mexico
Cardiolink Clin Trials S.C.
🇲🇽Monterrey, Nuevo Leon, Mexico
Centro de Investigación Cardiometabólica de Aguascalientes
🇲🇽Aguascalientes, Mexico
Academisch Medisch Centrum
🇳🇱Amsterdam, Netherlands
Rijnstate Ziekenhuis
🇳🇱Arnhem, Netherlands
Spaarne Gasthuis_Hoofddorp
🇳🇱Hoofddorp, Netherlands
Bravis Ziekenhuis
🇳🇱Roosendaal, Netherlands
Albert Schweitzer Ziekenhuis, locatie Zwijndrecht
🇳🇱Zwijndrecht, Netherlands
Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
🇵🇱Legnica, Poland
50BIO.COM Sp. z o.o.
🇵🇱Bydgoszcz, Kujawsko-Pomorskie Voivodeship, Poland
Gierach-Med
🇵🇱Bygdoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Terpa Sp. z o.o. Sp. k.
🇵🇱Lublin, Lubelskie Voivodeship, Poland
Instytut Diabetologii Sp. z o.o.
🇵🇱Warszawa, Mazovian Voivodeship, Poland
Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego
🇵🇱Warszawa, Poland
Centrum Medyczne Plejady
🇵🇱Krakow, Małopolskie, Poland
Uniwersytecki Szpital Kliniczny w Bialymstoku
🇵🇱Bialystok, Podlaskie Voivodeship, Poland
Gabinet Leczenia Otylosci i Chorob Dietozaleznych
🇵🇱Bialystok, Podlaskie Voivodeship, Poland
NZOZ Vita-Diabetica Malgorzata Buraczyk
🇵🇱Bialystok, Podlaskie Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Pomorskie, Poland
Centrum Medyczne Salvia
🇵🇱Katowice, Slaskie Voivodeship, Poland
Klinika Bellamed
🇵🇱Elblag, Warmińsko-Mazurskie, Poland
Centrum Zdrowia Metabolicznego
🇵🇱Poznan, Wielkopolskie Voivodeship, Poland
Centrum Ginekologii, Położnictwa i Leczenia Niepłodności
🇵🇱Poznań, Wielkopolskie Voivodeship, Poland
Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
🇷🇸Novi Sad, Serbia
Endocrinology, Diabetes and Metabolism Diseases Clinic
🇷🇸Belgrade, Serbia
Clinical Hospital Center Bezanijska Kosa
🇷🇸Belgrade, Serbia
East Rand Physicians
🇿🇦Johannesburg, Gauteng, South Africa
Dr R Dulabh
🇿🇦Johannesburg, Gauteng, South Africa
Dr Moosa's Rooms
🇿🇦Lenasia, Gauteng, South Africa
Shop#1 Health Emporium
🇿🇦Midrand, Gauteng, South Africa
Botho ke Bontle Health Services
🇿🇦Pretoria, Gauteng, South Africa
Dr Vawda's site
🇿🇦Durban, KwaZulu-Natal, South Africa
Dr J Reddy
🇿🇦Durban, KwaZulu-Natal, South Africa
Armansis Medical Centre
🇿🇦Brits, North West, South Africa
Southmead Hospital
🇬🇧Bristol, United Kingdom
Addenbrooke's Hospital_Cambridge
🇬🇧Cambridge, United Kingdom
Countess Of Chester NHS Foundation Trust
🇬🇧Chester, United Kingdom
Hathaway Medical Centre
🇬🇧Chippenham, United Kingdom
WISDEM Centre
🇬🇧Coventry, United Kingdom
University Hospital Aintree
🇬🇧Liverpool, United Kingdom
Guys Hospital
🇬🇧London, United Kingdom
Imperial College London
🇬🇧London, United Kingdom
UCL - Obesity
🇬🇧London, United Kingdom
Princess Royal University Hospital
🇬🇧Orpington, United Kingdom